Single-station skip-N2 disease: good prognosis in resected non-small-cell lung cancer (long-term results in skip-N2 disease)

被引:18
|
作者
Yazgan, Serkan [1 ]
Ucvet, Ahmet [1 ]
Gursoy, Soner [1 ]
Samancilar, Ozgur [1 ]
Yagci, Tarik [1 ]
机构
[1] Univ Hlth Sci, Dr Suat Seren Chest Dis & Surg, Med Practice & Res Ctr, Dept Thorac Surg, Izmir, Turkey
关键词
Non-small-cell lung cancer; Lymph node; Metastasis; MEDIASTINAL LYMPH-NODES; NEOADJUVANT CHEMOTHERAPY; PRIMARY TUMOR; N2; DISEASE; STAGE; METASTASIS; SURVIVAL; SURGERY; CARCINOMAS;
D O I
10.1093/icvts/ivy244
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES Pathological N2 (pN2) involvement has a negative impact on prognosis in patients operated on due to non-small-cell lung cancer (NSCLC). pN2 disease may cause skip (pN0N2) or non-skip (pN1N2) metastases with pathological N1 (pN1) involvement. The effect of pN2 subgroups on prognosis is still controversial. We analysed the effect of pN1 disease and single-station pN2 disease subgroups on survival outcomes. METHODS The medical records of patients who underwent anatomical lung resection due to NSCLC at a single centre between January 2007 and January 2017 were prospectively collected and retrospectively analysed. Operative mortality, sublobar resection, Stage IV disease, incomplete resection and carcinoid tumour were considered exclusion criteria. After histopathological examination, the prognosis of patients with pN1, pN0N2 and pN1N2 was compared statistically. Univariable and multivariable analyses were made to define independent risk factors for overall survival rates. RESULTS The mean follow-up time for 358 patients with 228 pN1 disease (63.7%), 59 pN0N2 disease (16.5%) and 71 pN1N2 disease (19.8%) was 40.430.4months. Median and 5-year overall survival rates for pN1, pN0N2 and pN1N2 diseases were 73.6months [95% confidence interval (CI) 55.5-91.7] and 54.1%, 60.3months (95% CI 26.8-93.8) and 51.2%, 20.8months (95% CI 16.1-25.5) and 21.5%, respectively. The survival CIs of pN1 and pN0N2 diseases were similar, and the survival rates of these 2 groups were significantly better than those with pN1N2 (P<0.001, P=0.001, respectively). In multivariable analysis, patients over the age of 60 [hazard ratio (HR) 2.13, P<0.001], patients not receiving adjuvant therapy (HR 1.52, P=0.01) and patients with pN1N2 disease (HR 2.91, P<0.001) had a poor prognosis. CONCLUSIONS Advanced age, not receiving adjuvant therapy and having pN1N2 disease are negative prognostic factors in patients with nodal involvement who underwent curative resection due to NSCLC. The overall survival and recurrence-free survival rates of pN1 disease and single-station pN0N2 disease are similar, and they have significantly better survival rates than pN1N2 disease. Based on these results, surgical treatment may be considered an appropriate choice in patients with histopathologically diagnosed single-station skip-N2 disease.
引用
收藏
页码:247 / 252
页数:6
相关论文
共 50 条
  • [41] Prognostic factors in resectable pathological N2 disease of non-small cell lung cancer
    Hsieh, Chen-Ping
    Fu, Jui-Ying
    Liu, Yun-Hen
    Yang, Cheng-Ta
    Hsieh, Ming-Ju
    Tsai, Ying-Huang
    Wu, Yi-Cheng
    Wu, Ching-Yang
    BIOMEDICAL JOURNAL, 2015, 38 (04) : 329 - 335
  • [42] The impact on the prognosis of unsuspected N2 disease in non-small-cell lung cancer: indications for thorough mediastinal staging in the modern era
    Ryosuke Tachi
    Aritoshi Hattori
    Takeshi Matsunaga
    Kazuya Takamochi
    Shiaki Oh
    Kenji Suzuki
    Surgery Today, 2017, 47 : 20 - 26
  • [43] The impact on the prognosis of unsuspected N2 disease in non-small-cell lung cancer: indications for thorough mediastinal staging in the modern era
    Tachi, Ryosuke
    Hattori, Aritoshi
    Matsunaga, Takeshi
    Takamochi, Kazuya
    Oh, Shiaki
    Suzuki, Kenji
    SURGERY TODAY, 2017, 47 (01) : 20 - 26
  • [44] Radiotherapy for patients with completely resected pathologic IIIA(N2) non-small-cell lung cancer: a retrospective analysis
    Zhu, Ying
    Fu, Lei
    Jing, Wang
    Kong, Li
    Yu, Jinming
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 10901 - 10908
  • [45] Management of stage IIIA (N2) non-small-cell lung cancer: a transatlantic perspectiveaEuro
    Rocco, Gaetano
    Nason, Katie
    Brunelli, Alex
    Varela, Gonzalo
    Waddell, Thomas
    Jones, David R.
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2016, 49 (04) : 1025 - 1027
  • [46] Re-appraisal of N2 disease by lymphatic drainage pattern for non-small-cell lung cancers: By terms of nodal stations, zones, chains, and a composite
    Zheng, Hui
    Wang, Lin-mao
    Bao, Fang
    Jiang, Ge-ning
    Xie, Hui-kang
    Ding, Jia-an
    Hu, Xue-fei
    Chen, Chang
    LUNG CANCER, 2011, 74 (03) : 497 - 503
  • [47] Long-term survival after complete resection of non-small-cell lung cancer in patients with interstitial lung disease
    Sekihara, Keigo
    Aokage, Keiju
    Oki, Tomonari
    Omori, Tomokazu
    Katsumata, Shinya
    Ueda, Takuya
    Miyoshi, Tomohiro
    Goto, Masaki
    Nakasone, Shoko
    Ichikawa, Tomohiro
    Hishida, Tomoyuki
    Yoshida, Junji
    Hisakane, Kakeru
    Goto, Koichi
    Tsuboi, Andmasahiro
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2018, 26 (04) : 638 - 643
  • [48] Feasibility and long-term efficacy of video-assisted thoracic surgery for unexpected pathologic N2 disease in non-small cell lung cancer
    Wang, Shaohua
    Zhou, Wenyong
    Zhang, Hui
    Zhao, Mingchuan
    Chen, Xiaofeng
    ANNALS OF THORACIC MEDICINE, 2013, 8 (03) : 170 - 175
  • [49] Long-term results of robotic anatomical segmentectomy for early-stage non-small-cell lung cancer
    Duy Nguyen
    Gharagozloo, Farid
    Tempesta, Barbara
    Meyer, Mark
    Gruessner, Angelika
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2019, 55 (03) : 427 - 433
  • [50] Neoadjuvant Chemotherapy With Docetaxel-Cisplatin in Patients With Stage III N2 Non-Small-Cell Lung Cancer
    Liao, Wei-Yu
    Chen, Jin-Hsin
    Wu, Muzo
    Shih, Jin-Yuan
    Chen, Kuan-Yuh
    Ho, Chao-Chi
    Yang, James Chih-Hsin
    Yu, Chong-Jen
    CLINICAL LUNG CANCER, 2013, 14 (04) : 418 - 424